Folgen
Dayu Lv
Dayu Lv
Research Scientist, Univ. of Virginia
Bestätigte E-Mail-Adresse bei virginia.edu
Titel
Zitiert von
Zitiert von
Jahr
The UVA/PADOVA type 1 diabetes simulator: new features
CD Man, F Micheletto, D Lv, M Breton, B Kovatchev, C Cobelli
Journal of diabetes science and technology 8 (1), 26-34, 2014
7562014
The UVA/Padova type 1 diabetes simulator goes from single meal to single day
R Visentin, E Campos-Náñez, M Schiavon, D Lv, M Vettoretti, M Breton, ...
Journal of diabetes science and technology 12 (2), 273-281, 2018
1892018
Adjustment of open-loop settings to improve closed-loop results in type 1 diabetes: a multicenter randomized trial
E Dassau, SA Brown, A Basu, JE Pinsker, YC Kudva, R Gondhalekar, ...
The Journal of Clinical Endocrinology & Metabolism 100 (10), 3878-3886, 2015
772015
Continuous glucose monitoring and insulin informed advisory system with automated titration and dosing of insulin reduces glucose variability in type 1 diabetes mellitus
MD Breton, SD Patek, D Lv, E Schertz, J Robic, J Pinnata, L Kollar, ...
Diabetes technology & therapeutics 20 (8), 531-540, 2018
762018
Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia
E Dassau, JE Pinsker, YC Kudva, SA Brown, R Gondhalekar, ...
Diabetes Care 40 (12), 1719-1726, 2017
762017
Empirical representation of blood glucose variability in a compartmental model
SD Patek, D Lv, EA Ortiz, C Hughes-Karvetski, S Kulkarni, Q Zhang, ...
Prediction methods for blood glucose concentration: Design, use and …, 2016
522016
Advanced hybrid artificial pancreas system improves on unannounced meal response-In silico comparison to currently available system
J Garcia-Tirado, D Lv, JP Corbett, P Colmegna, MD Breton
Computer Methods and Programs in Biomedicine 211, 106401, 2021
242021
Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients
D Lv, MD Breton, LS Farhy
Diabetes technology & therapeutics 15 (11), 935-941, 2013
202013
Pharmacokinetic model of the transport of fast-acting insulin from the subcutaneous and intradermal spaces to blood
D Lv, SD Kulkarni, A Chan, S Keith, R Pettis, BP Kovatchev, LS Farhi, ...
Journal of diabetes science and technology 9 (4), 831-840, 2015
142015
Determination of Henry’s law constant and the diffusion and polytropic coefficients of air in aviation fuel
PF Dunn, FO Thomas, JB Leighton, D Lv
Fuel 90 (3), 1257-1263, 2011
112011
Retrospective optimization of daily insulin therapy parameters: control subject to a regenerative disturbance process
SD Patek, D Lv, E Campos-Nanez, M Breton
IFAC-PapersOnLine 49 (7), 773-778, 2016
92016
Closing the loop
R Nimri, H Yakoob, B Schoenberg, E Dassau
Diabetes technology & therapeutics 18 (S1), S-29-S-42, 2016
82016
Multicenter outpatient randomized crossover trial of zone-MPC artificial pancreas in type 1 diabetes: effects of initialization strategies
E Dassau, SA Brown, A Basu, JE Pinsker, YC Kudva, R Gondhalekar, ...
Diabetes 64, A59-A60, 2015
42015
Pancreas modeling from ivgtt data using a deterministic optimal search method
D Lv, B Goodwine
2009 IEEE International Conference on Bioinformatics and Biomedicine, 303-308, 2009
22009
Preparation and electrochemical properties of layered manganese oxide (Li-birnessite type)
H Xing-kang, C Hai-tao, GAN Jian-long, Z Qing-shun, YUE Hong-jun, ...
Journal of Electrochemistry 15 (2), 194, 2009
22009
A New Metabolism Model for Human Skeletal Muscle.
D Lv, B Goodwine
BIODEVICES (2), 238-243, 2008
22008
Role of automated insulin delivery (artificial pancreas) in islet transplantation: An in silico assessment
D Lv, J Garcia-Tirado, C Fabris
OBM Transplantation 2 (3), 1-27, 2018
12018
THE DESIGN AND EVALUATION OF AN AUTOMATIC PRANDIAL INSULIN DOSING SYSTEM FOCUSED ON SAFETY
J Corbett, D Lv, M Breton
DIABETES TECHNOLOGY & THERAPEUTICS 23, A17-A18, 2021
2021
QUANTITATIVE PHYSIOLOGICAL ASSESSMENT, PREDICTION, AND SIMULATION OF CLINICAL SUBTYPES IN GLUCOSE METABOLISM DISORDERS
D Lv, J Thakur, C Fabris, L Farhy, M Breton, B Kovatchev
DIABETES TECHNOLOGY & THERAPEUTICS 23, A81-A81, 2021
2021
SLOWED MEAL APPEARANCE MAY ENABLE HYBRID CLOSED LOOP SYSTEM IN TYPE 1 DIABETIC PATIENTS: IN SILICO RESULTS
D Lv, M Breton
DIABETES TECHNOLOGY & THERAPEUTICS 21, A53-A53, 2019
2019
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20